NVAX Company Profile and Key Details

Q: Who are the executives of NVAX?

Mr. Biegie LeeSenior Vice President & Chief Information OfficerMr. Troy Morgan Esq., J.D.Senior Vice President & Chief Compliance OfficerMs. Erika S. TrahanAssociate Director of Investor & PRMr. Stanley Charles ErckAdvisorMr. John A. Herrmann IIIExecutive Vice President, Chief Legal Officer & Corporation Sec.Mr. Richard P. CrowleyExecutive Vice President & Chief Operating OfficerDr. Gregory M. GlennPres of R&DDr. Gale E. SmithSenior Vice President of Discovery & Pre-Clinical Research and Chief ScientistDr. Gregory M. Glenn M.D.Pres of R&DMr. John A. Herrmann III, J.D.Executive Vice President & Chief Legal OfficerMr. John Joseph Trizzino B.S., M.B.A.Executive Vice President, Chief Commercial Officer & Chief Bus. OfficerDr. Filip Dubovsky FAAP, M.D., M.P.H.Pres of R&DMs. Jill Hoyt SPHRExecutive Vice President & Chief HR OfficerMs. Silvia Taylor M.B.A., MBAExecutive Vice President and Chief Corporation Affairs & Advocacy OfficerMr. James Patrick Kelly C.F.A.Executive Vice President, Chief Financial Officer & Treasurer

NASDAQ : NVAX

Novavax

$7.70

-0.32-3.99%

At Close 4:00 PM

61.96

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Novavax, Inc. (NVAX) stock declined over -3.99%, trading at $7.70 on NASDAQ, down from the previous close of $8.02. The stock opened at $7.62, fluctuating between $7.57 and $7.91 in the recent session.

Stock Snapshot

8.02

Prev. Close

1.25B

Market Cap

7.565

Day Low

2.98

P/E Ratio

2.58

EPS (TTM)

-6.25

Cash Flow per Share

7.62

Open

162.94M

Number of Shares

7.91

Day High

84.18%

Free Float in %

-5.8

Book Value

4.6M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	7.70	7.91	7.57	7.70	4.65M
Apr 01, 2026	8.19	8.32	8.00	8.02	2.78M
Mar 31, 2026	8.27	8.39	7.72	8.14	5.86M
Mar 30, 2026	8.41	8.42	7.94	8.09	4.13M
Mar 27, 2026	8.84	8.96	8.44	8.45	3.86M
Mar 25, 2026	9.39	9.60	9.22	9.34	2.7M
Mar 24, 2026	9.52	9.73	9.25	9.26	3.16M
Mar 23, 2026	9.64	10.00	9.44	9.72	4.55M
Mar 20, 2026	9.84	10.00	9.42	9.62	5.67M
Mar 19, 2026	9.72	9.82	9.38	9.74	3.84M
Mar 18, 2026	10.63	10.80	10.00	10.01	3.87M
Mar 17, 2026	10.05	10.94	10.03	10.64	6.07M
Mar 16, 2026	10.42	10.47	9.95	10.08	3.32M
Mar 13, 2026	10.42	10.61	10.13	10.24	2.85M
Mar 12, 2026	10.78	10.81	10.27	10.30	3.6M
Mar 11, 2026	10.70	11.05	10.45	10.80	5.18M
Mar 10, 2026	10.57	10.82	10.44	10.69	3.58M
Mar 09, 2026	9.79	10.72	9.79	10.55	5.51M
Mar 06, 2026	9.75	10.05	9.53	9.98	3.79M
Mar 03, 2026	9.75	10.06	9.40	9.49	4.93M

Contact Details

Gaithersburg, MD 20878

United States

https://www.novavax.com 240 268 2000

About Company

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Stock Peers

REGN

-15.4-1.98%

Regeneron Pharmaceuticals, Inc.$761.85 ARGX

3.3+0.44%

argenx SE$746.42 UTHR

-5.46-0.96%

United Therapeutics Corporation$564.81 MDGL

17.05+3.22%

Madrigal Pharmaceuticals, Inc.$546.89 VRTX

-8.55-1.91%

Vertex Pharmaceuticals Incorporated$438.71 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-9.88-3.01%

Alnylam Pharmaceuticals, Inc.$318.85 PRAX

-8.9-2.79%

Praxis Precision Medicines, Inc.$310.38 KRYS

2.04+0.79%

Krystal Biotech, Inc.$260.95 ASND

1.01+0.44%

Ascendis Pharma A/S$229.25

Company Overview

Novavax, Inc. (NASDAQ:NVAX) closed at $7.70 USD, losing -$0.32 (-3.99%) from the previous close of $8.02. The stock is currently mid-range between its 52-week high and low $5.01 and $11.97. With a market capitalization of about $1.25 billion, Novavax, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.63). Key stats such as the average daily volume over the past year has been around 5.18 million shares, in line with its 52-week average. Headquartered in Gaithersburg, MD, Novavax, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John Charles Jacobs, the company employs approximately 952 people and listed since December 05, 1995. Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.

Technical Performance

NVAX has shown mixed momentum, gaining 5.81% over the past week and 1.23% over the past quarter, though year-to-date performance is up 22.02%. Short-term trend indicators are bearishly aligned (SMA20 25.32%, SMA50 36.65%, SMA200 45.03%). The stock’s 14-day RSI is 74.68 (overbought), while the ATR of 0.68 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 5.12% below its high and over 123.35% above its low. Average 10-day trading volume of 4.00 million shares is below the 3-month average of 5.18 million, indicating normal recent market interest.

Valuation Metrics

Novavax, Inc. trades at a P/E ratio of 2.83, slightly below the S&P 500 average, with a price-to-sales ratio of 1.12 and a price-to-book ratio of -9.76 indicating negative book value, which may reflect financial stress. The P/FCF stands at -5.01, also below market averages.

Dividend & Fair Value

Novavax, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $39.31. This means the shares are trading below this model’s fair value.

Shareholding & Insider Activity

Novavax, Inc. has 162.42 million shares outstanding. The public float is 136.72 million shares, elevated short interest at 23.54% of float. This equals 38.10 million shares. The short ratio is 5.25 days. Institutional investors hold 63.96% of the float. Insiders own 8.76%. Dubovsky Filip holds 66.61 thousand shares, YOUNG JAMES F has 51.76 thousand shares and King Rachel K. has 14.77 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Novavax generated $983.71M in revenue, or $9.76 per share. Gross margin was 71.59%, operating margin -42.19%, and net profit margin -55.41%. Returns are negative, with ROA at -29.38% and ROE at 76.03%.
On valuation metrics, Novavax trades at a P/E of 2.83, P/S of 1.12 and P/B of -9.76. The current ratio is 2.13 and quick ratio is 2.10. Operationally, the company’s inventory turnover is 6.50 and cash conversion cycle is -28.81 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -1.95, supported by a cash flow-to-debt ratio of -0.98.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Novavax posted revenue of $983.71M, down slightly from $1.60B in the prior quarter. Gross profit was $704.24M (margin 71.59%). Operating income was - $415.03M (margin -42.2%). Net income was- $545.06M (EPS - $5.41).
The company ended the quarter with $578.93M in cash and short-term investments, a total debt of $280.64M, and net debt of - $298.29M. Total assets were $1.86B, with equity of - $716.93M. Financials further reflected weakness, with operating cash flow of - $717.56M, free cash flow of - $776.36M, and capital expenditures of - $58.81M.

Price Forecast & Outlook

Our AI price prediction model suggests that Novavax, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -16.23%, with price expected at $6.45 by April 16, 2026, within a range of $5.92 to $6.97 3-Month Outlook: Projected rise of 3.64%, reaching $7.98 by July 01, 2026, with a range of $7.61 to $8.31. 1-Year Outlook: Projected gain of 290.52%, with price at $30.07 by April 02, 2027, within a range of $28.53 to $37.71.

Key Takeaways

Novavax, Inc. (NASDAQ:NVAX) shares are up 22.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Novavax, Inc. trading at a premium to the broader market with a P/E of 2.83. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $60.73, suggesting 688.7% upside. Our AI forecast model points to short-term weakness (-16.23% over two weeks), a medium-term rise (3.64% over three months), and a longer-term gain (290.52% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Novavax, Inc. (NVAX) stock price?

Novavax, Inc. (NASDAQ: NVAX) stock price is $7.70 in the last trading session. During the trading session, NVAX stock reached the peak price of $7.91 while $7.57 was the lowest point it dropped to. The percentage change in NVAX stock occurred in the recent session was -3.99% while the dollar amount for the price change in NVAX stock was - $0.32.

NVAX's industry and sector of operation?

The NASDAQ listed NVAX is part of Biotechnology industry that operates in the broader Healthcare sector. Novavax, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NVAX?

Mr. Biegie Lee
Senior Vice President & Chief Information Officer
Mr. Troy Morgan Esq., J.D.
Senior Vice President & Chief Compliance Officer
Ms. Erika S. Trahan
Associate Director of Investor & PR
Mr. Stanley Charles Erck
Advisor
Mr. John A. Herrmann III
Executive Vice President, Chief Legal Officer & Corporation Sec.
Mr. Richard P. Crowley
Executive Vice President & Chief Operating Officer
Dr. Gregory M. Glenn
Pres of R&D
Dr. Gale E. Smith
Senior Vice President of Discovery & Pre-Clinical Research and Chief Scientist
Dr. Gregory M. Glenn M.D.
Pres of R&D
Mr. John A. Herrmann III, J.D.
Executive Vice President & Chief Legal Officer
Mr. John Joseph Trizzino B.S., M.B.A.
Executive Vice President, Chief Commercial Officer & Chief Bus. Officer
Dr. Filip Dubovsky FAAP, M.D., M.P.H.
Pres of R&D
Ms. Jill Hoyt SPHR
Executive Vice President & Chief HR Officer
Ms. Silvia Taylor M.B.A., MBA
Executive Vice President and Chief Corporation Affairs & Advocacy Officer
Mr. James Patrick Kelly C.F.A.
Executive Vice President, Chief Financial Officer & Treasurer

How NVAX did perform over past 52-week?

NVAX's closing price is 53.69% higher than its 52-week low of $5.01 where as its distance from 52-week high of $11.97 is -35.67%.

How many employees does NVAX have?

Number of NVAX employees currently stands at 952.

Link for NVAX official website?

Official Website of NVAX is: https://www.novavax.com

How do I contact NVAX?

NVAX could be contacted at phone 240 268 2000 and can also be accessed through its website. NVAX operates from 21 Firstfield Road, Gaithersburg, MD 20878, United States.

How many shares of NVAX are traded daily?

NVAX stock volume for the day was 4.6M shares. The average number of NVAX shares traded daily for last 3 months was 5.18M.

What is the market cap of NVAX currently?

The market value of NVAX currently stands at $1.25B with its latest stock price at $7.70 and 162.94M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	952
Beta	2.63
Sales or Revenue	$983.71M
5Y Sales Change%	1.977%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

NVAX Company Profile and Key Details

Novavax

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook